Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;44(4):639-643.
doi: 10.1111/coa.13316. Epub 2019 Apr 1.

Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients

Ammar Sukari  1 , Misako Nagasaka  1   2 , Maria Diab  1 , Khaled Al Sibai  3 , Bassel Atassi  4 , Jailan A Elayoubi  5 , Seongho Kim  1 , Ömer Küçük  6
Affiliations

Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients

Ammar Sukari et al. Clin Otolaryngol. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

None to declare.

Figures

FIGURE 1
FIGURE 1
A, Kaplan-Meier Progression-free survival (PFS) by PS. B, Kaplan-Meier for Overall Survival (OS) after treatment by PS
See this image and copyright information in PMC

References

    1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. - PubMed
    1. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J clin oncol. 1992;10(8):1245–1251. - PubMed
    1. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J clin oncol. 2007;25(16):2171–2177. - PubMed
    1. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, Phase II Study. J Clin Oncol. 2017;35(14):1542–1549. - PMC - PubMed
    1. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–1867. - PMC - PubMed

MeSH terms